SCHEMBL4211571

SCHEMBL4211571

Cc1ccc(CNC(=O)c2c(N)cc(Cl)cc2Cl)cc1C

nearest known ligand 0.47

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 1/20 0.47
KMT2A Q03164 1/20 0.47
NR1H4 Q96RI1 1/20 0.45
ALDH2 P05091 3/20 0.44
HPGD P15428 3/20 0.43
NPC1 O15118 1/20 0.42
MMP13 P45452 1/20 0.41
WDR5 P61964 2/20 0.41
CNR1 P21554 1/20 0.41
THRB P10828 1/20 0.40
RAB9A P51151 1/20 0.40
KDM4E B2RXH2 1/20 0.40
ALDH1A1 P00352 1/20 0.40
HSD17B10 Q99714 1/20 0.40
TSHR P16473 1/20 0.40
TP53 P04637 1/20 0.39
MDM2 Q00987 1/20 0.39
CHRM4 P08173 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13744671 0.87 HPGD (0.53) MEN1KMT2AHPGDNPC1THRB
SCHEMBL4214266 0.85 CYP2C19 (0.53) MEN1KMT2AHPGDTHRBRAB9A
SCHEMBL13744508 0.84 MEN1 (0.43) MEN1KMT2AALDH2HPGDTHRB
SCHEMBL13744513 0.84 KDM4E (0.60) MEN1KMT2AHPGDMMP13THRB
SCHEMBL4223601 0.82 TP53 (0.50) KMT2AHPGDCNR1RAB9AALDH1A1
SCHEMBL13744662 0.82 TP53 (0.50) MEN1KMT2AHPGDTHRBALDH1A1
SCHEMBL4082388 0.82 NPC1 (0.51) MEN1KMT2AHPGDNPC1
SCHEMBL4223833 0.81 TP53 (0.54) MEN1KMT2AHPGDNPC1MMP13
SCHEMBL13744520 0.81 TP53 (0.59) MEN1KMT2ANR1H4HPGDNPC1
SCHEMBL4211740 0.80 CYP2C9 (0.49) MEN1KMT2AHPGDNPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090203708-A1 NOVEL SUBSTITUTED-1-H-QUINAZOLINE-2,4-DIONE DERIVATIVES, PREPARATION METHOD THEREOF AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) 2009-08-13 US disclosed
US-20090203708-A1 NOVEL SUBSTITUTED-1-H-QUINAZOLINE-2,4-DIONE DERIVATIVES, PREPARATION METHOD THEREOF AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) 2009-08-13 US disclosed
US-20090203708-A1 NOVEL SUBSTITUTED-1-H-QUINAZOLINE-2,4-DIONE DERIVATIVES, PREPARATION METHOD THEREOF AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) 2009-08-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090203708-A1 NOVEL SUBSTITUTED-1-H-QUINAZOLINE-2,4-DIONE DERIVATIVES, PREPARATION METHOD THEREOF AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME HTR5A, HTR3B, HTR1A MEN1 3793/4885KMT2A 4058/4885NR1H4 835/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.